November 21, 2016
A former Katten Muchin Rosenman LLP attorney charged with securities fraud alongside former Turing Pharmaceuticals Inc. head Martin Shkreli urged a New York federal judge Sunday to make the government spell out its allegations since it was wrong about when Katten represented a Shkreli-owned hedge fund.
November 16, 2016
Attorneys for former Turing Pharmaceuticals Inc. CEO Martin Shkreli on Wednesday said that former Shkreli-helmed drugmaker Retrophin Inc. has waived its attorney-client privilege with respect to communications with his former lawyers at Katten Muchin Rosenman LLP.
November 09, 2016
With Katten Muchin Rosenman LLP confronting ethically tricky questions about whether attorney-client privilege extends to corporate clients that no longer exist, the firm is wisely seeking an extra layer of legal cover before agreeing to hand over a trove of documents related to legal work done for former client Martin Shkreli and the firm's representation of more than a dozen of his ventures, experts say.
November 04, 2016
Katten Muchin Rosenman LLP on Thursday pushed to be spared from handing over likely privileged or excessive documents from its time counseling former Turing Pharmaceuticals Inc. CEO Martin Shkreli, telling a New York federal court that a sweeping subpoena covers years of work for multiple entities.
October 27, 2016
Former Turing Pharmaceuticals Inc. CEO Martin Shkreli on Thursday asked a New York federal court to make Katten Muchin Rosenman LLP hand over documents from its time representing him so he can fight the government's securities fraud charges by showing he acted in good faith after consulting the firm.
October 03, 2016
New York federal prosecutors on Friday urged a judge to reject bids by former Turing Pharmaceuticals Inc. CEO Martin Shkreli and his onetime attorney to compel more information from the government about the securities charges they face, saying the pair already has more than enough information to prepare for trial.
September 19, 2016
The former Kaye Scholer LLP partner charged with federal securities fraud alongside controversial former pharmaceutical executive Martin Shkreli told a New York federal judge on Friday that federal prosecutors should disclose more information about the charges against him so he can prepare his defense.
July 14, 2016
An attorney for former Turing Pharmaceuticals Inc. head Martin Shkreli on Thursday told a New York federal judge they will seek to sever his criminal securities fraud case from that of his onetime Kaye Scholer LLP attorney, as the judge set a June trial date.
June 06, 2016
Former Turing Pharmaceuticals Inc. boss Martin Shkreli and his onetime Kaye Scholer LLP attorney on Monday pled not guilty to a new fraud charge stemming from an alleged scheme to loot Retrophin Inc. to pay back hedge fund investors.
May 03, 2016
A prosecutor told Brooklyn U.S. District Judge Kiyo A. Matsumoto on Tuesday that pharma bad boy Martin Shkreli could face additional charges, possibly stemming from his alleged scheme to loot Retrophin Inc., where he had been an executive, to pay back hedge fund investors.